Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system.
about
Biomarkers for glioma immunotherapy: the next generationCell-of-origin of diffuse large B-cell lymphomas determined by the Lymph2Cx assay: better prognostic indicator than Hans algorithm.Gene Expression Profiling of Ewing Sarcoma Tumors Reveals the Prognostic Importance of Tumor-Stromal Interactions: A Report from the Children's Oncology GroupComparison of RNA-seq and microarray-based models for clinical endpoint prediction.Leveraging global gene expression patterns to predict expression of unmeasured genesKinase Gene Expression Profiling of Metastatic Clear Cell Renal Cell Carcinoma Tissue Identifies Potential New Therapeutic Targets.Clinical Application of Prognostic Gene Expression Signature in Fusion Gene-Negative Rhabdomyosarcoma: A Report from the Children's Oncology GroupArtificial neural network classifier predicts neuroblastoma patients' outcomeAn Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.Genetic discoveries and treatment advances in neuroblastoma.Detection of chromosomal translocations in formalin-fixed paraffin-embedded (FFPE) leukemic specimens by digital expression profiling.Incorporating genomic, transcriptomic and clinical data: a prognostic and stem cell-like MYC and PRC imbalance in high-risk neuroblastoma.Transcript signatures that predict outcome and identify targetable pathways in MYCN-amplified neuroblastomaIndividual patient risk stratification of high-risk neuroblastomas using a two-gene score suited for clinical use.NanoString expression profiling identifies candidate biomarkers of RAD001 response in metastatic gastric cancer.
P2860
Q26825496-ACE738AA-5586-41FE-93D4-E5071AA590DFQ33591789-E0E252E0-1001-4F05-A9EF-3F483B5AAA00Q35688154-4378BAAD-A70C-4CB7-A711-A223943B6DFBQ35863265-6C14AF24-6138-4255-A0F1-B4B4D4568F5CQ35868350-DB6D1F6B-1A41-4EFA-9AC2-94D54A61FB8CQ36116625-4EBB322D-E6B1-48DE-B053-4477E0372D8AQ36175120-2CB29340-0245-49AE-9BD5-467099519B18Q36276501-E2DF10C5-920F-4168-A017-BAE4E5107E08Q38603909-636A445D-8B4D-418D-BDB4-F7CC073B48ABQ38635551-92C5355A-C411-404F-942F-D53B690B5D78Q40285302-2235A47A-0E46-4859-A39C-B608E58CEE89Q42276835-992204B3-2CC8-4885-826B-83B5A725A878Q42282780-0E7D876E-9E51-4A3F-9327-4468067CB2D7Q49160323-B0030776-0917-46B5-89D1-066085D8EC40Q55077233-3E7EAB69-8400-43D8-9F12-80E4D3E28757
P2860
Validation of a prognostic multi-gene signature in high-risk neuroblastoma using the high throughput digital NanoString nCounter™ system.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 31 January 2014
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Validation of a prognostic mul ...... l NanoString nCounter™ system.
@en
Validation of a prognostic mul ...... l NanoString nCounter™ system.
@nl
type
label
Validation of a prognostic mul ...... l NanoString nCounter™ system.
@en
Validation of a prognostic mul ...... l NanoString nCounter™ system.
@nl
prefLabel
Validation of a prognostic mul ...... l NanoString nCounter™ system.
@en
Validation of a prognostic mul ...... l NanoString nCounter™ system.
@nl
P2093
P2860
P1433
P1476
Validation of a prognostic mul ...... l NanoString nCounter™ system.
@en
P2093
Alexandre Chlenski
Andres Morales La Madrid
Armita Bahrami
Elizabeth J Perlman
Helen R Salwen
Hiroyuki Shimada
Jason M Shohet
Julie R Park
Kirsteen H Maclean
Lisa Guerrero
P2860
P304
P356
10.1016/J.MOLONC.2014.01.010
P577
2014-01-31T00:00:00Z